Breo(SH:688793) Sou Hu Cai Jing·2026-02-11 08:23Core Viewpoint - The rapid rise and subsequent fall of Beilingsong and its founder Ma Xuejun illustrate the volatile nature of the capital market, where initial success can quickly turn into significant challenges and regulatory scrutiny [1][17]. Company Overview - Beilingsong, founded by Ma Xuejun, transitioned from a small health product company to a publicly listed entity on the STAR Market, achieving a market capitalization of over 100 billion yuan shortly after its IPO [7][10]. - The company initially focused on marketing, heavily investing in celebrity endorsements, which contributed to its rapid growth but also set the stage for future vulnerabilities [11][12]. Regulatory Issues - On December 25, 2025, Beilingsong announced that it and its actual controller Ma Xuejun were under investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations, leading to a 14.68% drop in stock price the following day [2][6]. - This was not the first time the company faced regulatory scrutiny; a self-inspection report revealed that Ma Xuejun had misappropriated 12.08 million yuan of company funds between 2021 and 2022 [4][5]. Financial Performance - Following its IPO, Beilingsong's financial performance deteriorated sharply, with a 24.7% decline in revenue in 2022, resulting in a net loss of 124 million yuan [13][14]. - Despite a revenue rebound to 1.275 billion yuan in 2023, the company continued to incur losses, with a projected net loss of 84 million to 105 million yuan for the entire year of 2025 [14][16]. Marketing Strategy - The company's aggressive marketing strategy, including high-profile endorsements from celebrities like Xiao Zhan and Yi Yang Qianxi, initially drove sales but later raised questions about sustainability and return on investment [11][12]. - Sales expenses remained disproportionately high, reaching 6.88 billion yuan in 2023, which accounted for 54% of revenue, indicating a troubling trend of high costs without corresponding revenue growth [14][16]. Challenges Ahead - As of early 2026, Beilingsong faced multiple challenges, including a significant drop in stock price (over 87% from its peak) and ongoing regulatory pressures [16]. - The company is attempting to pivot towards a new business model focused on "technology products + effective massage," but early results have shown a 34.07% decline in revenue for the first three quarters of 2025 [16].